Growth Hormone's Effect on the Cardiovascular System

Stopped early

Conditions studied: Growth Hormone Deficiency

In brief

To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-matched healthy population.

Key facts

Study ID

NCT00397319

Run by

Vanderbilt University

People needed

26

Starts

2005-08-01

Expected to finish

2006-12-01

Last updated by the study team

2007-07-03

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Adult between the ages of 18 and 65
• Documented Growth Hormone Deficiency as defined by a peak Growth Hormone during a GHRH-Arginine Stimulation test not exceeding 9.5 ng/ml

You may not qualify if…

• Personal history of cardiovascular disease (previous myocardial infarction or known coronary artery disease) or diagnosis of heart disease between study visits.
• Personal history of diabetes mellitus or development of diabetes between study visits.
• Initiation of an anti-cholesterol medication or anti-hypertensive between baseline and follow-up study visit.
• Initiation of regular tobacco use between baseline and follow-up study visit.
• Pregnancy or nursing
• Current daily use of any drug known to affect the fibrinolytic system: Aspirin, Aggrenox, Plavix, Persantine, Ticlid, Pletal, Trental, Lovenox, Coumadin, Agrylin, and Hydroxyurea.

Where it is running

• Vanderbilt University Medical Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.